CIN '2007 - 4th CONGRESS OF NEPHROLOGY IN INTERNET

Home

Welcome

Committees

• Organizing committee
• Honor committee
• Technical committee

Program

• Conferences
• Free papers

Participation

Sponsors

---

Rituximab and antineutrophil cytoplasmic antibody-associated vasculitis, future therapeutic hope?

Dr Christopher Wong

Department of Nephrology, Aintree University Hospital, Lower Lane, Liverpool

Abstract

Despite cyclophosphamide and steroids being the mainstay of treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), up to 10% of cases remain refractory [1]. For these refractory patients and those intolerant of the conventional therapy, recent successful report of response with rituximab (RIT) provide promising future therapeutic hope.

Full text

---

Comments:

---